Urology Times Innovation Celebration Video Series - Episode 11
"It is clearly the standard and it's the treatment of choice. When you have that, and it's very good, it's evidenced by the fact that none of the agents are compared against BCG because it sets such a high standard of effectiveness," says Sam S. Chang, MD, MBA.
As part of the Urology Times' 50th Anniversary Innovation Celebration, Sam S. Chang, MD, MBA, discusses the many ways in which BCG has improved the management of patients with bladder cancer. Chang is a Patricia and Rodes Hart professor of urology and oncology at the Vanderbilt University Medical Center and chief surgical officer at the Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.